All Stories

  1. Improved delivery of broadly neutralizing antibodies by nanocapsules suppresses SHIV infection in the CNS of infant rhesus macaques
  2. Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity
  3. Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses
  4. Simian-Human Immunodeficiency Virus SHIV.CH505 Infection of Rhesus Macaques Results in Persistent Viral Replication and Induces Intestinal Immunopathology
  5. Human natural killer cells mediate adaptive immunity to viral antigens
  6. IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine
  7. Divergent HIV-1-Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques
  8. Tribute to Bonnie Mathieson
  9. Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges
  10. Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials
  11. Passive and active antibody studies in primates to inform HIV vaccines
  12. Hepatocytic expression of human sodium-taurocholate cotransporting polypeptide enables hepatitis B virus infection of macaques
  13. Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge
  14. Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination
  15. Pre-existing neutralizing antibody mitigates B cell dysregulation and enhances the Env-specific antibody response in SHIV-infected rhesus macaques
  16. Use of broadly neutralizing antibodies for HIV-1 prevention
  17. E2 multimeric scaffold for vaccine formulation: immune response by intranasal delivery and transcriptome profile of E2-pulsed dendritic cells
  18. Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates
  19. Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides
  20. Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques
  21. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens
  22. Animal models in HIV-1 protection and therapy
  23. Functional and Molecular Characteristics of Novel and Conserved Cross-Clade HIV Envelope Specific Human Monoclonal Antibodies
  24. Tied down by its own receptor
  25. Multimeric Scaffolds Displaying the HIV-1 Envelope MPER Induce MPER-Specific Antibodies and Cross-Neutralizing Antibodies when Co-Immunized with gp160 DNA
  26. Development of Broadly Neutralizing Anti-HIV-1 Antibodies during Natural Infection through Early Epitope Acquisition and Subsequent Maturation
  27. Envelope Variants Circulating as Initial Neutralization Breadth Developed in Two HIV-Infected Subjects Stimulate Multiclade Neutralizing Antibodies in Rabbits
  28. Emergence of Broadly Neutralizing Antibodies and Viral Coevolution in Two Subjects during the Early Stages of Infection with Human Immunodeficiency Virus Type 1
  29. Vaccine Delivery to the Oral Cavity Using Coated Microneedles Induces Systemic and Mucosal Immunity
  30. Improvement of antibody responses by HIV envelope DNA and protein co-immunization
  31. HIV-1 Envelope Glycoprotein Resistance to Monoclonal Antibody 2G12 Is Subject-Specific and Context-Dependent in Macaques and Humans
  32. Neutralizing Polyclonal IgG Present during Acute Infection Prevents Rapid Disease Onset in Simian-Human Immunodeficiency Virus SHIVSF162P3-Infected Infant Rhesus Macaques
  33. SIV infection of rhesus macaques of Chinese origin: a suitable model for HIV infection in humans
  34. E2 multimeric scaffolds displaying HIV-1 Envelope regions elicit V3 and MPER-specific neutralizing antibody and T cell responses when combined with gp160 plasmid DNA
  35. Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially
  36. Lessons in Nonhuman Primate Models for AIDS Vaccine Research: From Minefields to Milestones
  37. Co-Immunization with Multimeric Scaffolds and DNA Rapidly Induces Potent Autologous HIV-1 Neutralizing Antibodies and CD8+ T Cells
  38. Neutralizing Antibodies and Control of HIV: Moves and Countermoves
  39. Sequential Immunization with a Subtype B HIV-1 Envelope Quasispecies Partially Mimics the In Vivo Development of Neutralizing Antibodies
  40. HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillus stearothermophilus induces sustained humoral and cellular immune responses in the absence of IFNγ production by CD4+ T cells
  41. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques
  42. Introduction
  43. Update on animal models for HIV research
  44. Blocking and tackling HIV
  45. Nonhuman primate models for pediatric AIDS
  46. The Infectious Molecular Clone and Pseudotyped Virus Models of Human Immunodeficiency Virus Type 1 Exhibit Significant Differences in Virion Composition with Only Moderate Differences in Infectivity and Inhibition Sensitivity
  47. Immune Responses to Measles and Tetanus Vaccines Among Kenyan Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Children Pre- and Post-Highly Active Antiretroviral Therapy and Revaccination
  48. High Specific Infectivity of Plasma Virus from the Pre-Ramp-Up and Ramp-Up Stages of Acute Simian Immunodeficiency Virus Infection
  49. Continuous Viral Escape and Selection by Autologous Neutralizing Antibodies in Drug-Naïve Human Immunodeficiency Virus Controllers
  50. Too close for comfort
  51. The Use of Nonhuman Primate Models in HIV Vaccine Development
  52. Pediatric AIDS: Maternal–Fetal and Maternal–Infant Transmission of Lentiviruses and Effects on Infant Development in Nonhuman Primates
  53. Transmission of HIV-1 in the Face of Neutralizing Antibodies
  54. Mutations in Envelope gp120 Can Impact Proteolytic Processing of the gp160 Precursor and Thereby Affect Neutralization Sensitivity of Human Immunodeficiency Virus Type 1 Pseudoviruses
  55. Macaques Infected with a CCR5-Tropic Simian/Human Immunodeficiency Virus (SHIV) Develop Broadly Reactive Anti-HIV Neutralizing Antibodies
  56. Evidence for Persistent, Occult Infection in Neonatal Macaques following Perinatal Transmission of Simian-Human Immunodeficiency Virus SF162P3
  57. Evaluation of Passively Transferred, Nonneutralizing Antibody-Dependent Cellular Cytotoxicity-Mediating IgG in Protection of Neonatal Rhesus Macaques against Oral SIVmac251 Challenge
  58. Insights into neutralizing antibodies and HIV Envelope
  59. Consistent Patterns of Change during the Divergence of Human Immunodeficiency Virus Type 1 Envelope from That of the Inoculated Virus in Simian/Human Immunodeficiency Virus-Infected Macaques
  60. Differentiation of a passive vaccine and the humoral immune response toward infection: Analysis of phage displayed peptides
  61. Animal models for perinatal transmission of HIV-1
  62. High Maternal HIV-1 Viral Load During Pregnancy Is Associated With Reduced Placental Transfer of Measles IgG Antibody
  63. Infection with a molecularly cloned SIVsm virus elicits high titer homologous neutralizing antibodies with heterologous neutralizing activity
  64. Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope
  65. Recommendations for the Design and Use of Standard Virus Panels To Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1 Vaccines
  66. Multigene DNA Priming-Boosting Vaccines Protect Macaques from Acute CD4+-T-Cell Depletion after Simian-Human Immunodeficiency Virus SHIV89.6P Mucosal Challenge
  67. New recombinant vaccines based on the use of prokaryotic antigen-display systems
  68. Perinatal transmission of SHIV-SF162P3 in Macaca nemestrina
  69. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin
  70. Passive Immunotherapy in Simian Immunodeficiency Virus-Infected Macaques Accelerates the Development of Neutralizing Antibodies
  71. Protective Immunity to SIV Challenge Elicited by Vaccination of Macaques with Multigenic DNA Vaccines Producing Virus-Like Particles
  72. Immunoprophylaxis to Prevent Mother-to-Child Transmission of HIV-1
  73. Macaque blood-derived antigen-presenting cells elicit SIV-specific immune responses
  74. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: Implications for HIV-1 vaccine development
  75. Multigene DNA Priming-Boosting Vaccines Protect Macaques from Acute CD4+-T-Cell Depletion after Simian-Human Immunodeficiency Virus SHIV89.6P Mucosal Challenge
  76. DNA vaccine strategies: candidates for immune modulation and immunization regimens
  77. Multigene DNA prime-boost vaccines for SHIV89.6P
  78. Role of neutralizing antibodies in HIV infection
  79. Determination of a Statistically Valid Neutralization Titer in Plasma That Confers Protection against Simian-Human Immunodeficiency Virus Challenge following Passive Transfer of High-Titered Neutralizing Antibodies
  80. Progress and challenges in therapies for AIDS in nonhuman primate models
  81. Immunization against SIVmne in macaques using multigenic DNA vaccines
  82. Neutralizing antibody responses in Africa green monkeys naturally infected with simian immunodeficiency virus (SIVagm)
  83. Protection from pathogenic SIV challenge using multigenic DNA vaccines
  84. Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell–free virions from blood plasma
  85. Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys
  86. Early Postinfection Antiviral Treatment Reduces Viral Load and Prevents CD4 + Cell Decline in HIV Type 2-Infected Macaques
  87. Titration of a Vaccine Stock Preparation of Human Immunodeficiency Virus Type 1 sf2 in Cultured Lymphocytes and in Chimpanzees
  88. Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile
  89. Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV-1SF2
  90. Characterization of a CD4-Expressing Macaque Cell Line That Can Detect Virus after a Single Replication Cycle and Can Be Infected by Diverse Simian Immunodeficiency Virus Isolates
  91. Fine Analysis of Humoral Antibody Response to Envelope Glycoprotein of SIV in Infected and Vaccinated Macaques
  92. Reduced Virus Load in Rhesus Macaques Immunized with Recombinant gp160 and Challenged with Simian Immunodeficiency Virus
  93. V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1.
  94. Nonaffinity Purification of Recombinant gp120 for Use in AIDS Vaccine Development
  95. B-Cell Abnormalities in AIDS: Stable and Clonally-Restricted Antibody Response in HIV-1 Infection
  96. HIV-1 Envelope gp120 Alters Astrocytes in Human Brain Cultures
  97. Molecular Profile of an Antibody Response to HIV-1 as Probed by Combinatorial Libraries
  98. Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis
  99. Inactivated Whole SIV Vaccine in Macaques: Evaluation of Protective Efficacy Against Challenge with Cell-Free Virus or Infected Cells
  100. SIV and FIV Vaccine Studies at UC Davis: 1991 Update
  101. Distinction of human immunodeficiency virus type 1 neutralization and infection enhancement by human monoclonal antibodies to glycoprotein 120.
  102. Antibodies are produced to the variable regions of the external envelope glycoprotein of human immunodeficiency virus type 1 in chimpanzees infected with the virus and baboons immunized with a candidate recombinant vaccine
  103. Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge.
  104. Functional and Immunological Characterization of SIV Envelope Glycoprotein Produced in Genetically Engineered Mammalian Cells
  105. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.
  106. Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells
  107. Antibody Reactivity to Deletion Mutants of the HIV-1 SF2 Envelope
  108. Priming of CD4+ T cells specific for conserved regions of human immunodeficiency virus glycoprotein gp120 in humans immunized with a recombinant envelope protein.
  109. Importance of Hypervariable Regions of HIV-1 gp120 in the Generation of Virus Neutralizing Antibodies
  110. Variants of human tissue-type plasminogen activator substituted at the protease cleavage site and glycosylation sites, and truncated at the N- and C-termini
  111. Locations of three repetitive sequence families found in BALB/c adult β-globin clones
  112. DNA sequence organization of the β-globin complex in the BALB/c mouse
  113. The recognition site of type II restriction enzyme BglI is interrupted
  114. Gene Enrichment
  115. Nonhuman Primate Models for AIDS